ARDX Stock News & Analysis | Latest Updates

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

June 18, 2025Lawsuits

ARDX News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX

Ardelyx Highlights Presentation At Digestive Disease Week 2025 Conference

Ardelyx Q1 GAAP EPS $(0.17) Misses $(0.12) Estimate, Sales $74.11M Miss $78.80M Estimate

Ardelyx To Present OPTIMIZE Study Supporting XPHOZAH At National Kidney Foundation Spring Clinical Meetings

Scotiabank Initiates Coverage On Ardelyx with Sector Outperform Rating, Announces Price Target of $15

Ardelyx's Tenapanor Approved In China For Hyperphosphatemia, Triggering $5M Milestone Payment

Raymond James Reiterates Strong Buy on Ardelyx, Lowers Price Target to $13

Breaking Down Ardelyx: 4 Analysts Share Their Views

HC Wainwright & Co. Reiterates Neutral on Ardelyx, Maintains $5.5 Price Target

Ardelyx Expects Full Year 2025 Us Net Product Sales Revenue For Ibsrela To Be Between $240M-$250M, Ardelyx Continues To Expect Ibsrela To Achieve Greater Than 10% Market Share At Peak And Generate More Than $1B In Annual U.S. Net Product Sales Revenue Bef

Ardelyx Q4 2024 GAAP EPS $0.02 Beats $0.01 Estimate, Sales $116.13M Beat $109.94M Estimate

Ardelyx Announces 2024 U.S. Sales Of $319M, Projects IBSRELA To Surpass $1B, XPHOZAH At $750M; Ends Year With $250M In Cash And Investments

Citigroup Maintains Buy on Ardelyx, Lowers Price Target to $10

HC Wainwright & Co. Reiterates Buy on Ardelyx, Maintains $11 Price Target

Ardelyx Beats Q3 Sales Estimates, Shares Climb

12 Health Care Stocks Moving In Thursday's After-Market Session

Ardelyx Q3 Sales $98.24M Beat $86.64M Estimate

Ardelyx Presents Additional Data On IBSRELA, A First-In-Class Treatment For IBS-C In Adults At The 2024 Digestive Disease Week Conference

10 Health Care Stocks Whale Activity In Today's Session

Ardelyx Showcases New Data At The NKF 2024 Spring Clinical Meetings On XPHOZAH